Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer

the ARMANI trial will test the hypothesis, if an anatomic resection (AR) improves long-term outcome vs. a non-anatomical resection (NAR) in patients undergoing surgery for RAS-mutated colorectal liver metastasis (CRLM).

Trial Details

NCT ID
NCT04678583
Phase
NA
Sponsor
Technische Universität Dresden
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Resection of colorectal liver metastases
Locations (sample)
  • Mannheim, Baden-Wurttemberg, Germany|49.4891,8.46694
  • Dresden, Saxony, Germany|51.05089,13.73832
  • Ansbach, Germany|49.30481,10.5931
  • Augsburg, Germany|48.37154,10.89851
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Colorectal cancer with RAS mutation (KRAS or NRAS)
  • Colorectal liver metastases (single or multiple)
  • Planned R0 resection of liver metastases (and primary tumor, if present)
  • Anatomical and non-anatomical liver resection technically feasible

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →